Research programme: c-Abl inhibitors - 1ST Bio/Neuraly

Drug Profile

Research programme: c-Abl inhibitors - 1ST Bio/Neuraly

Alternative Names: 1ST-102; Parkinson's disease therapeutics

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 1St Biotherapeutics
  • Developer 1St Biotherapeutics; Neuraly
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 25 Oct 2017 1ST Bio and Neuraly agree to co-develop c-Abl inhibitors in South Korea for Parkinson's disease
  • 25 Oct 2017 Preclinical trials in Parkinson's disease in South Korea (unspecified route)
  • 25 Oct 2017 1ST BIO intends to file an IND application for Parkinson's disease in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top